Navigation Links
Aisling Capital Announces Close of US$650M Life Sciences Fund
Date:1/7/2009

NEW YORK, Jan. 7 /PRNewswire/ -- Aisling Capital announced today that it raised US$650 million in committed capital for its newest life sciences fund, Aisling Capital III, LP. Aisling Capital will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry. With a total of over US$1.6 billion in committed capital under management, the Aisling Capital team will also continue to manage the Perseus-Soros BioPharmaceutical Fund, LP and Aisling Capital II, LP.

"We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence," commented Dennis Purcell, Senior Managing Partner of Aisling Capital. Mr. Purcell added: "We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor."

The Aisling Capital team is comprised of individuals with a combination of clinical, transactional, operational and capital markets expertise, complemented by extensive networks in the life sciences industry. The team is led by Managing Partners Dennis Purcell, Steve Elms and Andrew Schiff, M.D. and newly promoted Partners Dov Goldstein, M.D., Anthony Sun, M.D. and Brett Zbar, M.D. Additionally, Josh Bilenker, M.D. has been promoted to Principal.

About Aisling Capital

Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life
'/>"/>

SOURCE Aisling Capital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
2. Rigel to Participate at the RBC Capital Markets Healthcare Conference
3. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
4. Micromet to Present at the RBC Capital Markets Healthcare Conference
5. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
6. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
9. Medarex to Present at the RBC Capital Markets Healthcare Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and ... addition of Jain PharmaBiotech,s new report ... to their offering. The scope ... in situ hybridization (FISH), comparative genomic hybridization ... application of nanobiotechnology, microarrays, real-time polymerase chain ...
(Date:9/2/2015)... -- Australian prostate cancer technology company Minomic International Ltd ... ,outstanding, science that uses its patented antibody. ... prostate cancer diagnostic test known as MiCheck® next year, ... the peer-reviewed Australian Museum Eureka Science Prize for ... prize is awarded for ground breaking research that has ...
(Date:9/2/2015)... , September 2, 2015 BiondVax Pharmaceuticals ... the National Institute of Allergy and Infectious Diseases (NIAID), part ... Department of Health and Human Services (HHS), to launch a ... the United States in the 2015-16 timeframe. The ... candidate, Multimeric-001 (M-001), as a primer vaccine, which would be ...
(Date:9/2/2015)... ... 2015 , ... Temarry Recycling's new $100,000 waste to energy ... and continue to contribute to the sustainability of our natural resources. , Waste ... has been operating at their Mexico facility, Recicladora Temarry, for the last 7 ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... SANTA MONICA, Calif., April 23 Cord Blood America, ... stem cell preservation company ( http://www.cordblood-america.com ... of stem cells to families nationwide and internationally, which ... million in 2009, said today it has eliminated another ...
... April 23 Pharmalink AB today announced that ... company,s portfolio continues,to move towards late stage product ... advisors, Anders Wiklund,and Jens Christensen, are joining the ... business area at Industrifonden joins the Board,as the ...
... 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... regarding its SCORPION(TM) multispecific therapeutic technology at the ... Cancer Research (AACR) in Denver. The data presented ... bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific ...
Cached Biology Technology:Cord Blood America Further Reduction, $817,000, in Long-Term Debt 2Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development 2Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Ground-breaking research from Professor Douglas Kell, published in the ... the majority of debilitating illnesses are in part caused ... toxins that can react with the components of living ... diseases of many kinds in different parts of the ...
... N.Y. Pankaj Karande, a Rensselaer Polytechnic Institute assistant ... new generation of scientists and engineers developing exciting and ... complex brain illnesses, including Alzheimer,s disease, Parkinson,s disease, traumatic ... attracted the interest of the Goldhirsh Foundation and now ...
... The University of Pennsylvania, Dr. Ron Koder, assistant professor of ... of a team that devised a novel method for producing ... neuroglobin. He was recently awarded a three-year $1.3 million ... artificial blood that can be administered to injured troops on ...
Cached Biology News:See off Alzheimer's with the color purple 2Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 2Delivering drugs to the brain: New research into targeted treatment of Alzheimer's 3CCNY professor gets grant to develop 'artificial blood' 2
... amino acid acceptor activity using aminoacyl-tRNA synthetase and ... Ile, Lys, Pro, Thr, Val, Arg, Glu, His, ... unit will yield an A 260 of ... light path). Physical Form: lyophilized powder ...
... Immobilized White solid. PACKAGED UNDER INERT ... on polyacrylamide resin with applications similar to those ... 233156 , and 233155 ) but ... are added to the system. REDUCTACRYL™ Reagent can ...
... (hemagglutinating virus of Japan, also named Sendai ... for transfection of molecules by means of ... siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, Vector, ... vivo. GenomONE-Neo EX has a high fusing ...
... Dithiothreitol DTT White solid.. ... disulfides to thiols, so reaction is "driven" to ... not contain waxy surfactant found in many other ... pentobarbitol. Purity: ≥97% by titration. ...
Biology Products: